HuTARG™ Technology Applied to CDR Targeted Mutagenesis for Antibody Affinity Maturation
December 9, 2013
Burnaby, B.C., Canada. December 9th, 2013. – Innovative Targeting Solutions Inc. (ITS) a pioneer in novel protein engineering technologies, today announced the successful application of the company’s HuTARG technology for the affinity maturation of fully human antibodies. The HuTARG technology provides researchers with the ability to generate large library of variants exclusively targeting the CDRs, unlike error prone PCR, somatic hypermutation or other traditional mutagenesis approaches, leaving the antibody frameworks in germline configuration. Because the diversity is generated de novo, in vitro, by the HuTARG cell line itself, there is no manipulation of large recombinant libraries nor challenges due to the lower transformation rates of mammalian cells. The HuTARG technology is formatted so that antibodies are surface expressed and utilizing Fluorescence Activated Cell Sorting antibodies with greater than 10 folder improved affinities are easily identified and isolated in a single round of CDR optimization. Although the technology has been utilized to improve antibody affinities the technology can also be applied to identify mutations that improve expression of antibodies or other fusion proteins.
The data will be presented at IBC’s 2013 Antibody Engineering & Antibody Therapeutics conference and a copy of the poster can be downloaded from http://itsas01.azurewebsites.net/lin-et-al-antibody-engineering-2013/
About Innovative Targeting Solutions Inc.
Founded in 2008, Innovative Targeting Solutions Inc. is a privately‐held company that has developed the HuTARG technology a next generation protein engineering platform for the generation and maturation of fully human antibody therapeutics. The HuTARG technology is a fully mammalian technology that generates antibody diversity in vitro via RAG1/RAG2 mediated V(D)J recombination.